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ABSTRACT-A ten-year review of 198 patients with Stage 02 prostate cancer 
identijied 13 patients (6.6 %) who exhibited objective responses to hormonal 
treatment, as indicated by regression of a positive bone scan, CT scan, or chest 
x-ray j%lm. Four patients had complete responses and 9 patients achieved par- 
tial responses as judged by the National Prostatic Cancer Project criteria. Me- 
dian survival for those with objective treatment response has not yet been 
reached (>44 months) compared with twenty-four months for the nonrespon- 
ders (p = 0.00006). Although relatively uncommon, objective treatment re- 
sponse in Stage 02 prostate cancer is correlated with an improved prognosis. 
Since the early 194Os, hormonal therapy has 
been the standard of treatment for metastatic 
prostate cancer. Yet, little is known about objec- 
tive treatment response and its relation to prog- 
nosis. In the Veterans Administration Coopera- 
tive Urologic Research Group (VACURG), 
Bayard and associates’ reported that 10 percent 
of patients treated with endocrine therapy 
alone lived lon 
9 
er than ten years. It appears 
that the natura history of prostate cancer is 
variable and probably includes a subset of pa- 
tients whose response to hormonal treatment is 
unusually favorable. In an attempt to identify 
this patient group, we report our experience 
with hormonally treated patients with Stage D2 
prostate cancer over a ten-year period. 
Material and Methods 
We reviewed the charts of 198 patients with 
Stage D2 prostate cancer (extrapelvic metasta- 
sis) treated with hormonal therapy at the Uni- 
versity of Michigan Hospital from January 1981 
to January 199;l. Patient ages ranged from 
thirty-three to eighty-five years, with a median 
of 64.5 years. All patients had biopsy-proved 
prostate adenocarcinoma and evidence of Stage 
D2 disease on bone scan, computerized tomog- 
raphy (CT) scan, or chest x-ray film. The ma- 
jority of patients (136) presented initially with 
distant spread, while the remainder (62) pro- 
gressed to advanced disease after unsuccessful 
treatment for localized cancer. Each received 
hormonal treatment when distant metastasis 
was apparent. Hormonal therapy included 
single agent or combination treatment with es- 
trogens, LHRH agonists, flutamide, or bilateral 
orchiectomy. Follow-up radiographic studies 
were analyzed after initiation of treatment. 
Patients were evaluated for response using 
the criteria of the National Prostatic Cancer 
Project (NPCP).2 Criteria for a complete re- 
sponse (CR) included all of the following: (1) 
tumor masses which completely disappear, (2) 
normalization of acid phosphatase, (3) disap- 
pearance of osteolytic or osteoblastic lesions, (4) 
normalization of liver size or liver function 
tests, and (5) absence of new symptoms. Crite- 
ria for a partial response (PR) included any of 
the following: (1) recalcification of osteolytic 
lesions, (2) a 50 percent reduction in bone scan 
uptake or cross-sectional area of measurable le- 
sions, (3) a 30 percent reduction in liver size or 
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FIGURE 1. Bone scan dem- 
onstrating resolution of bony 
metastases (Pt. 2). (A) Prior to 
orchiectomy; (B) thirteen 
months postoperatively. 
FIGURE 2. Response of lymphatic metastases to en- 
docrine therapy (Pt. 9). (A) Pelvic CT (12/29/82) 
demonstrating a dilated left ureter (white arrow) 
and enlarged left pelvic lymph nodes (black arroux). 
Bilateral orchiectomy was performed January 3, 
1983. (B) CT (S/3/83) demonstrating a marked de- 
crease in the size of the lymphatic me&stases. (C) 
CT (10/18/83) showing resolution of the hydroure- 
ter. Reproduced with permission from Grossman 
HB: Hormonal therapy of prostatic carcinoma: is 
there a rationale for delayed treatment?, Urology 
27: 199 (1986). 
liver function tests, along with (4) normaliza- 
tion of acid phosphatase, and (5) absence of 
new symptoms or new sites of disease. In addi- 
tion, all responders (complete and partial) had 
normalization of prostate-specific antigen 
(PSA) when measured. 
Results 
Of the 198 patients, 13 (6.6%) exhibited an 
objective treatment response documented by re- 
gression of a positive bone scan, CT scan, or 
chest x-ray film (Figs. 1 and 2). Four patients 
had a complete response and 9 had a partial re- 
sponse as judged by criteria of the National 
Prostatic Cancer Project (Table I). Treatment 
response did not appear to be related to the 
method of hormonal ablation. Characteristics 
of the 13 responders included a mean age of 
63.1 years and a Gleason score ranging from 5 
to 9 with a median of 7. The nonresponder 
group included 185 patients with a mean age of 
64.7 years. Pathology reports were available for 
169 of these patients. The median Gleason score 
for the nonresponder group was also 7. 
Of the responders, 5 patients initially pre- 
sented with locoregional disease. Two of these 
patients presented initially as Stage B and were 
treated with radiation. One patient with Stage 
C disease underwent a radical prostatectomy. 
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TABLE I. Objective responders to endocrine therapy 
Duration 
Mets Site Treatment Response (Mos) Status 





I2188 12188 Bone 
12188 12188 Retroper. 
4189 4189 SC node 
9177 10/77 Bone 
6 62 5183 5183 
7 57 3185 3185 


















69 7187 7187 
67 10187 12188 

































( - ) CXR lo/88 31 Alive-CR 
( - ) bone scan 2190 
( - ) CT retroper. 
( - ) SC node 9190 
( -) bone scan 4181 
1 bone scan 2184 
( - ) bone scan 11/86 
1 bone scan 4190 
1 CT mediast. retroper. 
lymph nodes 3187 
( - ) CT retroper. lo/83 
1 bone scan 6185 
1 bone scan 12188 
( + ) bone scan 7189 
1 bone scan 4188 
1 SC node 4188 
1 bone scan 7189 













KEY: PLND = pelvic lymph node dissection; XRT = x-ray therapy; DES = diethylstilbestrol; arch. = orchiectomy; chemo. = 
chemotherapy; RRP = radical prostatectomq; retroper. = retroperitoneum; mediast. = mediastinum: SC = supraclavicular; CR = 
complete response; PR = partial response. 
Two patients were confirmed Stage Dl by 
pelvic lymph node dissection and received ra- 
diation. The remaining 8 patients in the respon- 
der group were diagnosed initially with Stage 
D2 disease. In all cases, patients received hor- 
monal therapy when progression to Stage D2 
was apparent. Sites of metastatic lesions in the 
responder group included bone in 10 patients, 
retroperitoneum or mediastinum in 3 patients, 
supraclavicular nodes in 2 patients, and lungs 
in 1 patient. 
Kaplan-Meier survival estimates show a sig- 
nificant difference between the nonresponder 
curve and the responder curve (Fig. 3) with 
p = 0.00006. M d e ian survival for the nonre- 
sponders is twenty-four months, which is simi- 
lar to other reported data in Stage D2 disease.3 4 
However, those patients with an objective treat- 
ment response have a median survival which 
has not yet been reached. 
Comment 
Of the 13 hormonal treatment responders, 2 Metastatic prostate cancer has been tradi- 
patients died at fifty months and one hundred tionally treated with androgen deprivation. 
eight months, respectively, for a mean survival Fifty years ago, Huggins and Hodges5 intro- 
of seventy-nine months. The 11 responders still duced castration and estrogen therapy as al- 
alive have a median survival to date of thirty- ternative forms of hormonal treatment. Al- 
one months, For the hormonal treatment non- though once widely prescribed, diethylstilbes- 
responders, median survival of the 107 expired trol is now used less frequently because of its 
patients was eighteen months. The remaining associated cardiovascular complications and the 
78 living patients have been followed for a me- development of other medical agents not as- 
dian of twelve months. sociated with cardiovascular morbidity, e.g., 
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GrOUQ 1: Nonresponoere N-187 
Group 2:COmplete and PWtml ReSDOnders Nsl3 
d I I I de 
time 
Survival m Metastatic Prostate Cancer 
(p = 0.0wo6) 
FIGURE 3. Kaplan-Meier survival curves, respon- 
ders vs nonresponders (time in month). 
luteinizing hormone-releasing hormone 
(LHRH) agonists and antiandrogens. Numer- 
ous studies have demonstrated the LHRH 
agonists to be equivalent to orchiectomy or DES 
as initial treatment of advanced prostate can- 
ceres7 Flutamide, a synthetic nonsteroidal anti- 
androgen, may be beneficial in combination 
with the LHRH agonists.s 
Median survival in Stage D2 prostate cancer 
patients treated with hormonal therapy is well 
documented and is generally reported at 
twenty-four to thirty months.3s4 Approximately 
80 percent of patients will respond initially to 
hormonal ablation, suggesting that most pros- 
tate cancer cells are androgen sensitivea 
Because relapse following an initial response 
to hormonal manipulation is common, the 
hypothesis has been proposed that most pros- 
tatic carcinomas are heterogeneous and are 
composed of both androgen-dependent and an- 
drogen-independent cells. lo-l2 Androgen with- 
drawal presumably depletes the androgen-de- 
pendent cells. However, eventual replacement 
by androgen-independent cells frequently oc- 
curs, resulting in ultimate treatment failure. 
As seen in the VACURG study, the time inter- 
val to failure is variable and includes a subset of 
patients who demonstrate a durable response to 
hormonal treatment. This translates into pro- 
longed survival which we hypothesized would 
correlate with objective treatment response. We 
identified 13 of 198 patients (6.6%) who exhib- 
ited objective treatment response by NPCP cri- 
teria. When compared with hormonal treat- 
ment nonresponders over the same time period, 
a striking survival advantage was seen. Using 
Kaplan-Meier estimates, a statistically signifi- 
cant difference was apparent between the re- 
sponder and nonresponder group (p = 
0.00006). The median survival for the nonre- 
sponders is twenty-four months. In contrast, 
the median survival for the responders has not 
yet been reached but is greater than forty-four 
months. This observation identifies the small 
group of patients who will respond extraor- 
dinarily well to hormonal treatment of meta- 
static prostate cancer. 
Why do some patients demonstrate an objec- 
tive treatment response and not others? It is not 
clear but appears unrelated to site of metastasis, 
type of hormonal therapy, or previous treat- 
ment. Nevertheless, an objective treatment re- 
sponse is an important prognostic indicator that 
provides optimism in the usually dismal setting 
of Stage D2 prostate cancer. We are continuing 
to investigate other parameters that may pro- 
vide early prediction of prolonged survival fol- 
lowing hormonal therapy. 
1500 E. Medical Center Drive 
Ann Arbor, Michigan 48109-0330 
(DR. GROSSMAN) 
References 
1. Bayard S, Greenberg R, Showalter D, and Byar D: Com- 
parison of treatment in prostate cancer using an exponential-type 
life model relating survival to concomitant information, Cancer 
Chemother Rep 58: 845 (1974). 
2. Slack N, et al: Criteria for evaluating patient responses to 
treatment modalities for prostatic cancer, Urol Clin North Am 11: 
337 (1984). 
3. Kozlowski J, and Grayhack J: Carcinoma of the Prostate, in 
Gillenwater J, et al. (Eds): Adult and Pediatric Urology, ed 2, 
Chicago, Year Book Medical Publishers, 1991, p 1000. 
4. Schroder F: Early versus delayed endocrine treatment in 
metastatic prostate cancer, in Murphy C, and Khoury S (Eds): 
Therapeutic Progress in Urological Cancers: Proceedings of an In- 
ternational Symposium held in Paris, France, June 29-July 1, 
1988. New York, Alan R. Liss, 1989, p 253. 
5. Huggins C, Stevens R, and Hodges C: Studies on prostatic 
cancer: effects of castration on advanced carcinoma of the pros- 
tate gland, Arch Surg 43: 209 (1941). 
6. Leuprolide Study Group: Leuprolide versus diethylstilbes- 
trol for metastatic prostate cancer, N Engl J Med 311: 1281 
(1984). 
7. Peeling WB: Phase III studies to compare goserelin (Zola- 
dex) with orchiectomy and with diethylstilbestrol in treatment of 
prostatic carcinoma, Urology (Supp15) 33: 45 (1989). 
8. Crawford ED, et al: A controlled trial of leuprolide with 
and without flutamide in prostatic carcinoma, N Engl J Med 321: 
419 (1989). 
9. Murphy GP, et al: Treatment of newly diagnosed metastatic 
prostate cancer patients with chemotherapy agents in combina- 
tion with hormones versus hormones alone, Cancer 51: 1264 
(1983). 
10. Bruchovsky N, et al: Effects of androgen withdrawal on 
the stem cell composition of the Shionogi carcinoma, Cancer Res 
50: 2275 (1990). 
11. Isaacs JT, and Kyprianou N: Development of androgen- 
independent tumor cells and their implication for the treatment 
of prostate cancer, Urol Res 15: 133 (1987). 
12. Isaacs JT, Schulze H, and Coffey DS: Development of an- 
drogen resistance in prostatic cancer, Prog Clin Biol Res 24314: 21 
(1987). 
408 UROLOGY I NOVEMBER 1992 / VOLUME 40, NUMBER 5 
